Gloveless isolators don’t end interventions. Learn to assess intervention dependency in robotic aseptic filling and when glove ports are justified.
Publication|Videos|May 13, 2024
Talking Strategic Development with Simtra at DCAT
Author(s)Simtra BioPharma Solutions
Ray Guidotti, Chief Operating Officer at Simtra BioPharma Solutions, talks about the company's strategic development and how it supports customers with a focus on excellence.
Simtra BioPharma Solutions is a premier contract development and manufacturing organization (CDMO) with more than 65 years of sterile injectable (SI) experience and a dedicated focus on providing a range of services from clinical development to commercial fill/finish. Learn more about:
- Simtra’s new building in Halle that features a high-speed syringe line and vial line equipped with four lyophilizers and is expected to be GMP ready in 2024.
- The new clinical line in Bloomington that will be ready to take on projects in the summer of 2025.
- Construction of the new state-of-the-art building in Bloomington that will begin in the summer of 2024.
Related to this article
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.
The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.
Terry Katz, CEO and cofounder of ForgeStop Technology Corporation, explains the company’s CPHI Award-winning connected product technology and how it helps to combat drug counterfeiting.
FDA approved pimicotinib for TGCT based on a 56% response rate; its Project Orbis review signals tighter global launch planning for manufacturers.
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
$1.15B AI-Guided Macrocycle Discovery Lands at argenx
3
Pimicotinib TGCT Approval Shows How Assessment Aid Supports Review
4
Our Biggest Takeaways From AAPS PharmSci 360
5